Eli Lilly And Co (LLY) Position Lifted by Farmers & Merchants Investments Inc.

Share on StockTwits

Farmers & Merchants Investments Inc. increased its holdings in Eli Lilly And Co (NYSE:LLY) by 6.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 48,578 shares of the company’s stock after acquiring an additional 2,973 shares during the quarter. Farmers & Merchants Investments Inc.’s holdings in Eli Lilly And Co were worth $5,213,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in the stock. Palladium Partners LLC lifted its stake in shares of Eli Lilly And Co by 1.5% in the third quarter. Palladium Partners LLC now owns 233,918 shares of the company’s stock worth $25,102,000 after acquiring an additional 3,380 shares in the last quarter. Arizona State Retirement System lifted its stake in shares of Eli Lilly And Co by 0.8% in the third quarter. Arizona State Retirement System now owns 278,567 shares of the company’s stock worth $29,893,000 after acquiring an additional 2,174 shares in the last quarter. Greenleaf Trust lifted its stake in shares of Eli Lilly And Co by 11.2% in the third quarter. Greenleaf Trust now owns 10,919 shares of the company’s stock worth $1,172,000 after acquiring an additional 1,104 shares in the last quarter. Columbus Circle Investors acquired a new position in shares of Eli Lilly And Co in the third quarter worth about $21,099,000. Finally, Wagner Bowman Management Corp lifted its stake in shares of Eli Lilly And Co by 5.2% in the third quarter. Wagner Bowman Management Corp now owns 14,904 shares of the company’s stock worth $1,599,000 after acquiring an additional 730 shares in the last quarter. Institutional investors and hedge funds own 76.36% of the company’s stock.

NYSE LLY traded up $0.26 on Tuesday, hitting $107.66. 104,316 shares of the stock traded hands, compared to its average volume of 5,063,431. Eli Lilly And Co has a twelve month low of $73.69 and a twelve month high of $116.61. The stock has a market capitalization of $114.26 billion, a P/E ratio of 25.23, a PEG ratio of 1.73 and a beta of 0.29. The company has a quick ratio of 1.09, a current ratio of 1.40 and a debt-to-equity ratio of 0.79.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 10th. Shareholders of record on Thursday, November 15th will be paid a dividend of $0.5625 per share. This represents a $2.25 annualized dividend and a yield of 2.09%. The ex-dividend date is Wednesday, November 14th. Eli Lilly And Co’s payout ratio is currently 52.57%.

Several research firms recently commented on LLY. Credit Suisse Group boosted their price target on Eli Lilly And Co from $84.00 to $86.00 and gave the stock an “underperform” rating in a research note on Wednesday, July 25th. JPMorgan Chase & Co. set a $123.00 price target on Eli Lilly And Co and gave the stock a “buy” rating in a research note on Friday, October 5th. Bank of America boosted their price target on Eli Lilly And Co from $90.00 to $94.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 25th. Cantor Fitzgerald set a $100.00 price objective on Eli Lilly And Co and gave the company a “buy” rating in a research note on Tuesday, July 24th. Finally, Goldman Sachs Group set a $100.00 price objective on Eli Lilly And Co and gave the company a “neutral” rating in a research note on Wednesday, July 25th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and twelve have issued a buy rating to the stock. Eli Lilly And Co presently has an average rating of “Buy” and an average target price of $111.53.

In other Eli Lilly And Co news, insider Donald A. Zakrowski sold 600 shares of the company’s stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $105.57, for a total transaction of $63,342.00. Following the sale, the insider now owns 3,530 shares in the company, valued at $372,662.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Lilly Endowment Inc sold 190,000 shares of the company’s stock in a transaction that occurred on Thursday, August 2nd. The shares were sold at an average price of $99.58, for a total value of $18,920,200.00. Following the sale, the insider now owns 120,946,601 shares in the company, valued at approximately $12,043,862,527.58. The disclosure for this sale can be found here. Insiders have sold 1,570,271 shares of company stock worth $162,683,202 in the last 90 days. 0.11% of the stock is currently owned by insiders.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: Balanced Fund

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply